Print Page  Close Window

Investor Relations
Corporate Profile

We are Zogenix.

Zogenix is committed to developing therapies that address specific clinical needs for people living with CNS and pain-related conditions who need innovative treatment alternatives to help them return to normal daily functioning.

A significant number of patients are not being effectively treated, despite the availability of current therapies. These patients deserve access to safe and effective treatments. Zogenix is committed to ensuring the safe and appropriate use of our products ... More >>

Latest PresentationsMore >>
Title
Download Documentation Zogenix February 2015 Investor Presentation
Get help downloading or viewing the above file types
Stock Quote
ZGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.40
Change (%)0.00 (0.00%)
Volume2,142,653
Data as of 05/22/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
05/11/15Zogenix Provides Corporate Update and Reports First Quarter 2015 Financial Results
Company Will Host a Conference Call Today at 4:30 p.m. EDT/1:30 p.m. PDT SAN DIEGO, May 11, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, provided a corporate update, and announced financial results for the first quarter ended March 31, 2015. Corporate Update Appointed Stephen J. Farr, Ph.D., previously serving as the Company's President, as the new ... 
Printer Friendly Version
05/04/15Zogenix to Release First Quarter 2015 Financial Results and Host Conference Call & Webcast on May 11
SAN DIEGO, May 4, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2015 after the market close, and will host a corporate update conference call and webcast on Monday, May 11, 2015 at 4:30pm Eastern Time. Monday, May 11, 2015 @ 4:30pm Eastern Time/1:30pm ... 
Printer Friendly Version
04/27/15Dr. Stephen Farr Appointed as CEO of Zogenix to Lead New Strategic Focus and Advance Late-Stage CNS Product Pipeline
SAN DIEGO, April 27, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that it is implementing its succession plan as the Company focuses on advancing its late-stage product development pipeline. Zogenix's Board of Directors has unanimously appointed Stephen Farr, Ph.D., previously serving as the Company's President, as Roger Hawley's successor and new... 
Printer Friendly Version
04/24/15Zogenix Closes Sale of Zohydro(R) ER Business to Pernix
Strategic Focus Shifts to Zogenix's High Value Late-Stage CNS Pipeline SAN DIEGO, April 24, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that it has closed the sale of its Zohydro® ER (hydrocodone bitartrate) business to a wholly-owned subsidiary of Pernix Therapeutics Holdings, Inc. (Nasdaq:PTX) for $80 million in cash, approximately 1.68 millio... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.